Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Simple item page
dc.contributor.authorKarakaş A.
dc.contributor.authorGulle S.
dc.contributor.authorCan G.
dc.contributor.authorDalklllc E.
dc.contributor.authorAkar S.
dc.contributor.authorKoca S.S.
dc.contributor.authorPehlivan Y.
dc.contributor.authorSenel S.
dc.contributor.authorTufan A.
dc.contributor.authorOzturk M.A.
dc.contributor.authorYilmaz S.
dc.contributor.authorYazici A.
dc.contributor.authorCefle A.
dc.contributor.authorYüce Inel T.
dc.contributor.authorErez Y.
dc.contributor.authorSari I.
dc.contributor.authorBirlik M.
dc.contributor.authorDireskeneli H.
dc.contributor.authorAkkoc N.
dc.contributor.authorOnen F.
dc.date.accessioned2024-07-22T08:01:23Z
dc.date.available2024-07-22T08:01:23Z
dc.date.issued2024
dc.description.abstractObjectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results: There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P =. 003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P >. 05). Conclusions: This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. © 2023 Japan College of Rheumatology. Published by Oxford University Press. All rights reserved.
dc.identifier.DOI-ID10.1093/mr/road061
dc.identifier.issn14397595
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11428
dc.language.isoEnglish
dc.publisherOxford University Press
dc.subjectAdult
dc.subjectAntibodies, Monoclonal
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectObesity
dc.subjectSpondylitis, Ankylosing
dc.subjectTreatment Outcome
dc.subjectsecukinumab
dc.subjectmonoclonal antibody
dc.subjectsecukinumab
dc.subjectadult
dc.subjectankylosing spondylitis
dc.subjectArticle
dc.subjectbody mass
dc.subjectcohort analysis
dc.subjectdisease activity
dc.subjectdrug retention
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectobesity
dc.subjectobservational study
dc.subjectpsoriasis
dc.subjectsacroiliac joint
dc.subjectsacroiliitis
dc.subjectsurvival
dc.subjectsurvival rate
dc.subjecttreatment response
dc.subjectankylosing spondylitis
dc.subjectcomplication
dc.subjectmiddle aged
dc.subjectobesity
dc.subjecttreatment outcome
dc.titleDoes obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
dc.typeArticle

Files

Collections

Scopus Koleksiyonu